Pet Health was the largest of Elanco Animal Health Inc’s 5 reported lines in fiscal 2025, at $4.60B — 49% of $9.43B.
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Pet Health | $4.28B | $4.21B | $4.29B | $4.60B | ||||||
| Farm Animal | — | — | — | — | ||||||
| Food Animal Ruminants Swine | — | — | — | — | ||||||
| Farm Animal Ruminants Swine | — | — | — | — | ||||||
| Cattle | $1.89B | $1.90B | $2.01B | $2.25B | ||||||
| Pet Health Disease Prevention | — | — | — | — | ||||||
| Poultry | $1.43B | $1.53B | $1.59B | $1.72B | ||||||
| Farm Animal Future Protein Health | — | — | — | — | ||||||
| Companion Animal Disease Prevention | — | — | — | — | ||||||
| Food Animal Future Protein Health | — | — | — | — | ||||||
| Swine | $768.00M | $764.00M | $732.00M | $758.00M | ||||||
| Pet Health Therapeutics | — | — | — | — | ||||||
| Companion Animal Therapeutics | — | — | — | — | ||||||
| Aqua | $350.00M | $350.00M | $162.00M | — | ||||||
| Companion Animal Other | — | — | — | — | ||||||
| Contract Manufacturing & Other | — | $84.00M | $92.00M | $106.00M | ||||||
| Contract Manufacturing | $108.00M | — | — | — | ||||||
| Strategic Exits | — | — | — | — | ||||||
| Total | $8.82B | $8.83B | $8.88B | $9.43B |
In fiscal 2025, which ended December 31, 2025, the 5 revenue lines Elanco Animal Health Inc reported in this breakdown added up to $9.43B. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $8.88B reported that year. Pet Health was the largest revenue line, at $4.60B or 48.8% of the total, followed by Cattle ($2.25B, 23.9%) and Poultry ($1.72B, 18.2%). Together, the two largest revenue lines made up 72.6% of this total.
Compared with fiscal 2024, Cattle grew the fastest, rising 11.7% to $2.25B. Every sizeable revenue line reported in both years grew. Because revenue lines were added or dropped between the two years, part of this reflects how Elanco Animal Health Inc regrouped its reporting.
Contract Manufacturing & Other was first reported as a separate revenue line in fiscal 2023. The table also keeps 13 revenue lines that Elanco Animal Health Inc no longer reports, so earlier years can still be read on their original basis; use "Show 13 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Elanco Animal Health Inc's annual filings.
International was the largest of Elanco Animal Health Inc’s 2 reported lines in fiscal 2025, at $4.96B — 53% of $9.43B.
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| International | $4.89B | $4.87B | $4.81B | $4.96B | ||||||
| Non-Us | — | — | — | — | ||||||
| Next Largest Country | — | — | — | — | ||||||
| United States | $3.93B | $3.97B | $4.07B | $4.47B | ||||||
| Total | $8.82B | $8.83B | $8.88B | $9.43B |
In fiscal 2025, which ended December 31, 2025, the 2 regions Elanco Animal Health Inc reported in this breakdown added up to $9.43B. That was up 6.2% from $8.88B in fiscal 2024. International was the largest region, at $4.96B or 52.6% of the total, followed by United States ($4.47B, 47.4%).
Compared with fiscal 2024, United States grew the fastest, rising 9.7% to $4.47B. Over fiscal 2022 to 2025, revenue across these regions went from $8.82B to $9.43B, a compound annual growth rate of 2.2%. International's share of the total fell from 55.5% to 52.6% over the same years.
The table also keeps 2 regions that Elanco Animal Health Inc no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Elanco Animal Health Inc's annual filings.
As Reported was the largest of Elanco Animal Health Inc’s 2 reported lines in fiscal 2022, at $2.06B — 100% of $2.05B.
| Revision of Prior Period | FY 2020 | FY 2021 | FY 2021 | FY 2021 | FY 2021 | FY 2022 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| As Reported | $6.55B | $2.48B | $2.56B | $2.26B | $9.53B | $2.45B | $2.35B | $2.06B |
| Revisions | -$4.00M | $2.00M | -$2.00M | — | -$2.00M | $2.00M | -$4.00M | -$4.00M |
| Total | $6.54B | $2.49B | $2.56B | $2.26B | $9.53B | $2.45B | $2.35B | $2.05B |
In fiscal 2022, which ended September 30, 2022, the 2 revenue lines Elanco Animal Health Inc reported in this breakdown added up to $2.05B. That was down 12.7% from $2.35B in fiscal 2022. As Reported was the largest revenue line, at $2.06B or 100.2% of the total.
Over fiscal 2020 to 2022, revenue across these revenue lines went from $6.54B to $2.05B, a compound annual decline of 44.0%. As Reported held a steady share of about 100.2%.
Figures are shown as reported, so the total is net of Revisions, which was -$4.00M in fiscal 2022. This breakdown covers 8 fiscal years between 2020 and 2022, as reported in Elanco Animal Health Inc's annual filings.
Elanco Animal Health Inc (ELAN) breaks its revenue down by revenue line and region. In fiscal 2025, its largest revenue line was Pet Health, with $4.60B or 48.8% of the total, followed by Cattle at $2.25B (23.9%).
Pet Health was Elanco Animal Health Inc's largest revenue line in fiscal 2025, with $4.60B in revenue, 48.8% of the $9.43B reported across its 5 revenue lines.
International was Elanco Animal Health Inc's largest region in fiscal 2025, with $4.96B in revenue, 52.6% of the $9.43B reported across its 2 regions.
Of the Elanco Animal Health Inc regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, United States grew the fastest, rising 9.7% from $4.07B to $4.47B.
Every figure is taken from Elanco Animal Health Inc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2016 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.